Sage Therapeutics appoints Barry Greene as CEO

pharmafile | December 18, 2020 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Sage Therapeutics, a biopharmaceutical company focused on developing treatments for central nervous system disorders, has appointed Barry Greene as Chief Executive Officer in a move to accelerate the company’s growth and leverage the talents of the leaders in the brain health space.

Greene, who most recently served as President of Alnylam Pharmaceuticals from 2007 to September of this year, and as its Chief Operating Officer from 2003 to 2016, will also continue as a member of Sage’s board of directors. Prior to his 17-year tenure at Alnylam, Greene was the General Manager of Oncology at Millennium Pharmaceuticals, where he led the company’s global strategy and execution for its oncology business.

Sage’s previous CEO, Dr Jeff Jonas, will remain in the company as its Chief Innovation Officer. He will also remain a member of the board and will chair Sage’s Science & Technology Forum of the Board.

Greene said of his appointment: “Sage is taking on one of the biggest challenges we face today with the urgent and escalating need for more options to transform the lives of millions of patients with debilitating brain health disorders.

“Together, Jeff with his unique neuroscience expertise, and I, along with the talented team at Sage, can leverage our collective strengths in our efforts to bring new options to patients in areas that have been lacking innovation for a very long time. I look forward to being part of such a passionate and committed team as we advance Sage’s multi-franchise strategy and work to deliver on our mission to bring positive impact to the lives of many patients and their families.”

Kevin Starr, Chairman of the Board at Sage, said Greene’s appointment as CEO is “the result of thoughtful succession discussions with the Board, with the aim of augmenting the executive bench with a world-class leader committed to moving Sage to the next stage of growth and commercialization.

“Barry is ideal to lead this mission: he has a significant track record of successfully executing on R&D and commercialization strategies. He has built and grown a multiproduct company and is very familiar with Sage’s business and culture. Having Barry as CEO and Jeff as CInO strengthens Sage for its next evolution.”

Related Content

No items found

Latest content